Aromatase Inhibitors: Current Indications and Future Prospects for Treatment of Postmenopausal Breast Cancer

Journal of the American Geriatrics Society

Volumn 52, Issue 4, 2004, Pages 611-616

  Arora, Amit ^a,b   Potter, Jane F ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Estrogen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FADROZOLE; FLUVESTRANT; FORMESTANE; GESTAGEN; IMIDAZOLE; IMIDE; LETROZOLE; MEGESTROL; OMEPRAZOLE; PHENYTOIN; PROPANOL; PYRIDOGLUTETHIMIDE; QUINOLONE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STEROID; TAMOXIFEN; TOREMIFENE; TRIAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOROZOLE; WARFARIN;

ACNE; ADVANCED CANCER; AGE; ALOPECIA; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RECURRENCE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FRACTURE; FUTUROLOGY; GASTROINTESTINAL SYMPTOM; GENDER; GERIATRIC PATIENT; HOARSENESS; HOT FLUSH; HUMAN; HYPERTRICHOSIS; INFORMATION PROCESSING; KIDNEY FAILURE; LANGUAGE; LITERATURE; MEDLINE; METASTASIS; MUSCULOSKELETAL DISEASE; OSTEOLYSIS; PALLIATIVE THERAPY; POSTMENOPAUSE; REVIEW; SIDE EFFECT; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG APPROVAL; DRUG INTERACTIONS; ECONOMICS, PHARMACEUTICAL; FEMALE; FORECASTING; GERIATRICS; HUMANS; NEOADJUVANT THERAPY; NITRILES; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 1842733426     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2004.52171.x     Document Type: Review

References (31)

1. Ries LAG, Kosary CL, Hankey BF et al. SEER Cancer Statistics Review 1973-96. Bethesda, MD: Nationzl Cancer Institute, 1999.
2. Clemons M, Gross PE. Estrogen and risk of breast cancer. N Engl J Med 2002;346:340-352.
3. Tilson-Mallett N, Santner SJ, Feil RD et al. Biological significance of aromatase activity in human breast tumors. J Clin Endocrinol Metab 1983; 57:1125-1128.
4. Kimmick GG, Muss HB. Systemic therapy for older women with breast cancer. Oncology 2001;15:280-291.
5. Iveson TJ, Smith IE, Ahern J et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993;77:324-331.
6. Yates RA, Dowsett M, Fisher GV et al. 'Arimidex' (ZD1033). 1996;73:543-548.
7. Di Salle E, Giudici D, Briatico G et al. Novel irreversible aromatase inhibitors. Ann N Y Acad Sci 1990;595:357-367.
8. Geisler J. In vivo inhibition of aromatization by exemestane: A novel irreversible aromatase inhibitor in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-2093.
9. Buzdar AU, Jones SE, Vogel CL et al. for the Arimidex Study Group. A Phase III trial comparing anastrozole (1 and 10 mg), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancer. Cancer 1997;79:730-739.
10. Wiseman LR, Adkins JC. Anastrozole. A review of its use in postmenopausal women with advanced breast cancer. Drugs 1998;56:1125-1140.
11. Geisler J, King N, Dowsett M et al. Influence of anastrozole ('Arimidex'), a selective, nonsteroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in post-menopausal women with breast cancer. Br J Cancer 1996;74:1286-1291.
12. Lamb HM, Adkins JC. Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Drugs 1998;56:1125-1140.
13. Lonning PE. Pharmacological profiles of exemestane and formestanc, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Res Treat 1998;49(Suppl 1):S45-S52.
14. Geisler J, King N, Anker G et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-2093.
15. Ingle JN, Suman VJ, Johnson PA et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetics interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res 1999;5:1642-1649.
16. Elisaf MS, Bairaktari ET, Nicolaides C et al. Effect of letrozole on the lipid in postmenopausal women with breast cancer. Eur J Cancer 2001;37:1510-1513.
17. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606.
18. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758-3767.
19. Bonneterre J, Thurlimann B, Robertson JFR et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women Results of the Tamoxifen or Arimidex. Randomized Group Efficacy and Tolerability Study. J Clin Oncol 2000;18:3748-3757.
20. Buzdar AU, Jonat W, Howell A et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998;83:1142-1152.
21. Kaufmann M, Bajetta E., Dirix LY et al. Exemestane improves survival compared with megestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. Eur J Cancer 2000;36(Suppl 4):86-87.
22. Dombernowsky P, Smith I, Falkson G et al. Letrozole for advanced breast cancer. Double blind randomized trail showing dose-effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16:453-461.
23. Baum M, Buzdar AU, Cuzick J et al. for the ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 2002;359:2131-2139.
24. Winer E, Hudis C, Burnstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women hormone receptor-positive breast cancer: Status report 2000. J Clin Oncol 2002;20(20):3317-3327.
25. Buzdar A. for the ATAC Trialists' Group The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer-updated efficacy results based on a median follow-up of 47 months. Breast Cancer Res Treat 2003;77:295.
26. Geisler J, Bernsten L, Ottestad L et al. Comparison of the effects of neoadjuvant 'Arimidex' (anastrozole) on plasma and intratumor tissue estrogen levels in postmenopausal breast cancer patients. Breast 1999;8:241.
27. Paepke S, Apffelstaedt J, Eremin J et al. Neo-adjuvant treatment of postmenopausal breast cancer patients with letrozole (Femara): A randomized study versus tamoxifen. Eur J Cancer 2000;36(Suppl 5):S76.
28. Dowsett M, Geisler J, Haynes BP et al. Letrozole achieves more complete inhibition of whole body aromatisation than anastrozole. Eur J Cancer 2000;36(Suppl 5):S88.
29. Mullins CD. An overview of cancer economics. Am J Manag Care 1999; 5(Suppl 6):371-S376.
30. Simon MS et al. Efficacy and economics of hormonal therapies for advanced breast cancer. Drugs Aging 2002;19:453-454.
31. Nuijten M, Meester L, Waibel F et al. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. Pharmacoeconomics 1999;16:379-397.